Package Leaflet: Information for the User
CELSENTRI 25mg film-coated tablets
CELSENTRI 75mg film-coated tablets
CELSENTRI 150mg film-coated tablets
CELSENTRI 300mg film-coated tablets
maraviroc
Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.
Contents of the pack
CELSENTRI contains the active substance maraviroc. Maraviroc belongs to a group of medicines called CCR5 antagonists. CELSENTRI works by blocking the CCR5 receptor, which HIV uses to enter and infect blood cells.
CELSENTRI is used to treat HIV-1 infection in adults, adolescents, and children aged 2 years and older, weighing at least 10 kg.
CELSENTRI must be taken in combination with other medicines that are also used to treat HIV infection. All these medicines are called anti-HIV medicines or antiretrovirals.
CELSENTRI, as part of combination therapy, reduces the amount of virus in your body and keeps it at a low level. This helps your body to increase the number of CD4 cells in the blood. CD4 cells are a type of white blood cell that are important for helping your body to fight infections.
Do not take CELSENTRI
Warnings and precautions
Talk to your doctor or pharmacist before taking or administering CELSENTRI.
Your doctor should take blood samples to see if CELSENTRI is a suitable treatment for you (or your child).
Some people taking CELSENTRI have developed severe allergic reactions or skin reactions (see also “Severe side effects” in section 4).
Before taking this medicine, make sure your doctor knows if you (or your child) have or have had any of the following problems:
Conditions to be aware of
Some people taking medicines for HIV infection develop other conditions, which can be serious. These include:
You need to know what important signs and symptoms to look out for while taking CELSENTRI.
Elderly patients
Only a limited number of people aged 65 years or older have taken CELSENTRI. If you belong to this age group, consult your doctor to see if you can take CELSENTRI.
Children
The use of CELSENTRI has not been tested in children under 2 years of age or weighing less than 10 kg. Therefore, CELSENTRI is not recommended for children under 2 years of age or weighing less than 10 kg.
Other medicines and CELSENTRI
Tell your doctor or pharmacistif you (or your child) are taking,have recently taken, or might take any other medicines.
Tell your doctor or pharmacist if you (or your child) start taking a new medicine while taking CELSENTRI.
It is likely that medicines containing St. John's Wort (Hypericum perforatum) will stop CELSENTRI from working properly. Do not take it while taking CELSENTRI.
Some medicines may affect the levels of CELSENTRI in the body when taken at the same time as CELSENTRI. These include:
Pregnancy and breastfeeding
If you are pregnant, think you may be pregnant, or are planning to have a baby:
It is not recommendedthat HIV-infected women breastfeed their babies because HIV infection can be passed to the baby through breast milk.
It is not known if the components of CELSENTRI can also pass into breast milk. If you are breastfeeding or thinking of breastfeeding, consult your doctor as soon as possible.
Driving and using machines
CELSENTRI may make you feel dizzy.
CELSENTRIcontains soy lecithin and sodium.
Do not take this medicine if you are allergic to peanuts or soy.
CELSENTRI contains less than 1 mmol of sodium (23 mg) per tablet; this is, essentially “sodium-free”.
Always take this medicine exactly as your doctor has told you. If you are not sure, check with your doctor or pharmacist.
If you (or your child) are unable to swallow the tablets, your doctor will consider whether it is better for you (or your child) to take the oral solution of CELSENTRI.
How much to take
Adults
The recommended dose of CELSENTRI is 150 mg, 300 mg, or 600 mg twice a day, depending on whether you are taking other medicines at the same time.Always take the dose recommended by your doctor.
People with kidney problems
If you have kidney problems, your doctor may adjust your dose.
Adolescents and children aged 2 years and older and weighing at least 10 kg
Your doctor will tell you the correct dose of CELSENTRI based on weight and other medicines being taken at the same time.
CELSENTRI can be taken with or without food.CELSENTRI should always be taken orally.
CELSENTRI must be taken in combination with other medicines used to treat HIV. Check the package leaflet of these other medicines to find out how to take them.
If you take or give more CELSENTRI than you should
If you accidentally take or give too much CELSENTRI
If you forget to take or give CELSENTRI
If you (or your child) miss a dose of CELSENTRI, take or give it as soon as possible and continue with the next dose at the usual time.
If it is almost time for the next dose, do not take or give the missed dose. Wait and take the next dose at the usual time.
Do not take or give a double dose to make up for missed doses.
If you (or your child) stop taking CELSENTRI
Continue treatment with CELSENTRI until your doctor tells you to stop.
It is important that you (or your child) take your medicines every day, as this will help to prevent the HIV infection from progressing in your body. Therefore, unless your doctor tells you to stop, it is important that you (or your child) continue treatment with CELSENTRI as described above.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, CELSENTRI can cause side effects, although not everybody gets them. Tell your doctor about any unusual changes in your health or your child's health.
Severe side effects - seek medical help immediately
Severe allergic reactions or skin reactions
Some people taking CELSENTRI have developed severe skin reactions and severe allergic reactions that can be life-threatening. These are rare, can affect up to 1 in 1,000 peopletaking CELSENTRI.
If you have any of these symptoms while being treated with CELSENTRI:
Liver problems
These are rare and can affect up to 1 in 1,000 peopletaking CELSENTRI.
The signs include:
Other side effects
Common side effects
These can affect up to 1 in 10 people:
Uncommon side effects
These can affect up to 1 in 100 people:
Rare side effects
These can affect up to 1 in 1,000 people:
Other possible side effects of combination antiretroviral therapy for HIV
People taking combination antiretroviral therapy for HIV may develop other side effects.
Symptoms of infection and inflammation
People with advanced HIV infection (AIDS) have a weakened immune system and are more likely to develop serious infections (opportunistic infections). After starting treatment, the immune system becomes stronger, so the body starts to fight off these infections.
Symptoms of infection and inflammationmay develop, caused by:
Symptoms of autoimmune disorderscan appear many months after starting to take medicines for HIV infection. The symptoms can include:
If you have any symptoms of infection or if you notice any of the above symptoms:
Pain in the joints, stiffness, and bone problems
Some patients on combination antiretroviral therapy for HIV develop a condition called osteonecrosis. In this condition, parts of the bone tissue die due to a reduction in blood supply to the bones.
The frequency of this condition is not known. It is more likely to develop:
Signs to look out for include:
If you notice any of these symptoms:
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist, even if they are not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use CELSENTRI after the expiry date which is stated on the carton, blister, or label of the bottle. The expiry date is the last day of the month stated.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of CELSENTRI
Tablet core: microcrystalline cellulose, anhydrous calcium hydrogen phosphate, sodium starch glycolate, magnesium stearate.
Coating: poly(vinyl alcohol), titanium dioxide (E171), macrogol 3350, talc, soybean lecithin, aluminum lake of indigo carmine (E132).
Appearance and Package Contents of the Product
The film-coated tablets of CELSENTRI are blue, engraved with "MVC 25", "MVC 75", "MVC 150", or "MVC 300".
CELSENTRI 25 mg and 75 mg film-coated tablets are supplied in bottles of 120 tablets.
CELSENTRI 150 mg and 300 mg film-coated tablets are supplied in bottles of 60 tablets or in blisters of 30, 60, or 90 film-coated tablets and in multiple packs containing 180 (2 packs of 90) film-coated tablets.
Only certain pack sizes may be marketed.
Marketing Authorization Holder:
ViiV Healthcare BV, Van Asch van Wijckstraat 55H, 3811 LP Amersfoort, Netherlands.
Manufacturer:
Pfizer Manufacturing Deutschland GmbH, Mooswaldallee 1, 79108 Freiburg Im Breisgau, Germany.
For further information about this medicinal product, please contact the local representative of the marketing authorization holder:
Belgium/Belgique/Belgien ViiV Healthcare srl/bv Tel: + 32 (0) 10 85 65 00 | Lithuania ViiV Healthcare BV Tel: +370 80000334 |
Luxembourg/Luxemburg ViiV Healthcare srl/bv Belgium/Belgien Tel: + 32 (0) 10 85 65 00 | |
Czech Republic GlaxoSmithKline s.r.o. Tel: + 420 222 001 111 cz.info@gsk.com | Hungary ViiV Healthcare BV Tel.: +36 80088309 |
Denmark GlaxoSmithKline Pharma A/S Tlf: + 45 36 35 91 00 dk-info@gsk.com | Malta ViiV Healthcare BV Tel: +356 80065004 |
Germany ViiV Healthcare GmbH Tel.: + 49 (0)89 203 0038-10 viiv.med.info@viivhealthcare.com | Netherlands ViiV Healthcare BV Tel: + 31 (0)33 2081199 |
Estonia ViiV Healthcare BV Tel: +372 8002640 | Norway GlaxoSmithKline AS Tlf: + 47 22 70 20 00 |
Greece GlaxoSmithKline Μονοπρóσωπη A.E.B.E. Τηλ: + 30 210 68 82 100 | Austria GlaxoSmithKline Pharma GmbH Tel: + 43 (0)1 97075 0 at.info@gsk.com |
Spain Laboratorios ViiV Healthcare, S.L. Tel: + 34 900 923 501 es-ci@viivhealthcare.com | Poland GSK Services Sp. z o.o. Tel.: + 48 (0)22 576 9000 |
France ViiV Healthcare SAS Tél.: + 33 (0)1 39 17 6969 Infomed@viivhealthcare.com | Portugal VIIVHIV HEALTHCARE, UNIPESSOAL, LDA. Tel: + 351 21 094 08 01 viiv.fi.pt@viivhealthcare.com |
Croatia ViiV Healthcare BV Tel: +385 800787089 | Romania ViiV Healthcare BV Tel: +40 800672524 |
Ireland GlaxoSmithKline (Ireland) Limited Tel: + 353 (0)1 4955000 | Slovenia ViiV Healthcare BV Tel: +386 80688869 |
Iceland Vistor hf. Sími: + 354 535 7000 | Slovak Republic ViiV Healthcare BV Tel: +421 800500589 |
Italy ViiV Healthcare S.r.l. Tel: + 39 (0)45 7741600 | Finland GlaxoSmithKline Oy Puh/Tel: + 358 (0)10 30 30 30 Finland.tuoteinfo@gsk.com |
Cyprus ViiV Healthcare BV Τηλ: +357 80070017 | Sweden GlaxoSmithKline AB Tel: + 46 (0)8 638 93 00 info.produkt@gsk.com |
Latvia ViiV Healthcare BV Tel: +371 80205045 |
Date of the Last Revision of this Leaflet: {MM/YYYY}
Other Sources of Information
Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu/.